Casein kinase 1δ/ε inhibitor PF-5006739 attenuates opioid drug-seeking behavior

ACS Chemical Neuroscience

Volumn 5, Issue 12, 2014, Pages 1253-1265

  Wager, Travis T ^a   Chandrasekaran, Ramalakshmi Y ^a   Bradley, Jenifer ^a   Rubitski, David ^a   Berke, Helen ^a   Mente, Scot ^a   Butler, Todd ^a   Doran, Angela ^a   Chang, Cheng ^a   Fisher, Katherine ^a   Knafels, John ^a   Liu, Shenping ^a   Ohren, Jeff ^a   Marconi, Michael ^a   DeMarco, George ^a   Sneed, Blossom ^a   Walton, Kevin ^b   Horton, David ^a   Rosado, Amy ^a   Mead, Andy ^a  

^a PFIZER INC   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Casein kinase 1; Circadian rhythm; CK1 ; CK1 ; Drug addiction; Dual inhibitor; Opioid reinstatement; PF 5006739; Phase delaying

Indexed keywords

4 [4 (4 FLUOROPHENYL) 1 (PIPERIDIN 4 YL) 1H IMIDAZOL 5 YL]PYRIMIDIN 2 AMINE; 4 [4 (4 FLUOROPHENYL) 1 [1 (1,2 OXAZOL 3 YLMETHYL)PIPERIDIN 4 YL] 1H IMIDAZOL 5 YL]PYRIMIDIN 2 AMINE; 4 [4 (4 FLUOROPHENYL) 1 [1 (1,2,4 OXADIAZOL 3 YLMETHYL)PIPERIDIN 4 YL] 1H IMIDAZOL 5 YL]PYRIMIDIN 2 AMINE; 4 [4 (4 FLUOROPHENYL) 1 [1 (3,3,3 TRIFLUOROPROPYL)PIPERIDIN 4 YL] 1H IMIDAZOL 5 YL]PYRIMIDIN 2 AMINE; 4 [4 (4 FLUOROPHENYL) 1 [1 (PYRIDIN 2 YLMETHYL)PIPERIDIN 4 YL] 1H IMIDAZOL 5 YL]PYRIMIDIN 2 AMINE; 4 [4 (4 FLUOROPHENYL) 1 [1 (PYRIMIDIN 2 YLMETHYL)PIPERIDIN 4 YL]1H IMIDAZOL 5 YL]PYRIMIDIN 2 AMINE; AMINE; BENZYL 4 FORMYLPYRIMIDIN 2 YLCARBAMATE; BENZYL [4 [1 (1 BENZYLPIPERIDIN 4 YL) 4 (4 FLUOROPHENYL) 1H IMIDAZOL 5 YL]PYRIMIDIN 2 YL]CARBAMATE; BENZYL [4 [[(1 BENZYLPIPERIDIN 4 YL)IMINO]METHYL]PYRIMIDIN 2 YL]CARBAMATE; CASEIN KINASE IDELTA; CASEIN KINASE IEPSILON; FENTANYL; OPIATE; PF 5006739; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; 4-(4-(4-FLUOROPHENYL)-1-(1-(1,2-OXAZOL-3-YLMETHYL)PIPERIDIN-4-YL)-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-AMINE; CASEIN KINASE I; ENZYME INHIBITOR; ISOXAZOLE DERIVATIVE; NARCOTIC ANALGESIC AGENT; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EXPOSURE; DRUG PENETRATION; DRUG POTENCY; DRUG SEEKING BEHAVIOR; DRUG SELECTIVITY; DRUG SELF ADMINISTRATION; DRUG STRUCTURE; DRUG SYNTHESIS; EC50; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; IC50; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; SUBSTANCE ABUSE; ANALYSIS OF VARIANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMISTRY; CROSSOVER PROCEDURE; DRUG EFFECTS; HUMAN; INSTRUMENTAL CONDITIONING; MACACA FASCICULARIS; PROTEIN TRANSPORT; RANDOMIZED CONTROLLED TRIAL; RAT; REINFORCEMENT; SPRAGUE DAWLEY RAT; TIME;

ANIMALIA; RODENTIA;

ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; ANIMALS; CASEIN KINASE I; CIRCADIAN RHYTHM; CONDITIONING, OPERANT; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-SEEKING BEHAVIOR; ENZYME INHIBITORS; FENTANYL; HUMANS; ISOXAZOLES; MACACA FASCICULARIS; MICE; MICE, INBRED C57BL; PROTEIN TRANSPORT; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; REINFORCEMENT (PSYCHOLOGY); SELF ADMINISTRATION; TIME FACTORS;

EID: 84918592404     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn500201x     Document Type: Article

References (37)

1. Degenhardt, L., Whiteford, H. A., Ferrari, A. J., Baxter, A. J., Charlson, F. J., Hall, W. D., Freedman, G., Burstein, R., Johns, N., Engell, R. E., Flaxman, A., Murray, C. J. L., and Vos, T. (2013) Global burden of disease attributable to illicit drug use and dependence: Findings from the Global Burden of Disease Study. 2010. Lancet 382, 1564-1574.
2. Gallego, M., and Virshup, D. M. (2007) Post-translational modifications regulate the ticking of the circadian clock. Nat. Rev. Mol. Cell Biol. 8, 139-148.
3. Meng, Q.-J., Maywood, E. S., Bechtold, D. A., Lu, W.-Q., Li, J., Gibbs, J. E., Dupré, S. M., Chesham, J. E., Rajamohan, F., Knafels, J., Sneed, B., Zawadzke, L. E., Ohren, J. F., Walton, K. M., Wager, T. T., Hastings, M. H., and Loudon, A. S. I. (2010) Entrainment of disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymes. Proc. Natl. Acad. Sci. U.S.A. 107, 15240-15245.
4. Ralph, M., and Menaker, M. (1988) A mutation of the circadian system in golden hamsters. Science 241, 1225-1227.
5. Lowrey, P. L., Shimomura, K., Antoch, M. P., Yamazaki, S., Zemenides, P. D., Ralph, M. R., Menaker, M., and Takahashi, J. S. (2000) Positional Syntenic Cloning and Functional Characterization of the Mammalian Circadian Mutation tau. Science 288, 483-491.
6. Xu, Y., Padiath, Q. S., Shapiro, R. E., Jones, C. R., Wu, S. C., Saigoh, N., Saigoh, K., Ptacek, L. J., and Fu, Y.-H. (2005) Functional consequences of a CK1[delta] mutation causing familial advanced sleep phase syndrome. Nature 434, 640-644.
7. Jones, C. R., Campbell, S. S., Zone, S. E., Cooper, F., DeSano, A., Murphy, P. J., Jones, B., Czajkowski, L., and Ptacek, L. J. (1999) Familial advanced sleep-phase syndrome: A short-period circadian rhythm variant in humans. Nat. Med. 5, 1062-1065.
8. Walton, K. M., Fisher, K., Rubitski, D., Marconi, M., Meng, Q.-J., Sladek, M., Adams, J., Bass, M., Chandrasekaran, R., Butler, T., Griffor, M., Rajamohan, F., Serpa, M., Chen, Y., Claffey, M., Hastings, M., Loudon, A., Maywood, E., Ohren, J., Doran, A., and Wager, T. T. (2009) Selective inhibition of casein kinase 1ε minimally alters circadian clock period. J. Pharmacol. Exp. Ther. 330, 430-439.
9. Falcón, E., and McClung, C. A. (2009) A role for the circadian genes in drug addiction. Neuropharmacology 56 ((Suppl 1)), 91-96.
10. Abarca, C., Albrecht, U., and Spanagel, R. (2002) Cocaine sensitization and reward are under the influence of circadian genes and rhythm. Proc. Natl. Acad. Sci. U.S.A. 99, 9026-9030.
11. Spanagel, R., Pendyala, G., Abarca, C., Zghoul, T., Sanchis-Segura, C., Magnone, M. C., Lascorz, J., Depner, M., Holzberg, D., Soyka, M., Schreiber, S., Matsuda, F., Lathrop, M., Schumann, G., and Albrecht, U. (2005) The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. Nat. Med. 11, 35-42.
12. Perreau-Lenz, S., Vengeliene, V., Noori, H. R., Merlo-Pich, E. V., Corsi, M. A., Corti, C., and Spanagel, R. (2012) Inhibition of the Casein-Kinase-1-Epsilon/Delta Prevents Relapse-Like Alcohol Drinking. Neuropsychopharmacology 37, 2121-2131.
13. Svenningsson, P., Nairn, A. C., and Greengard, P. (2005) DARPP-32 mediates the actions of multiple drugs of abuse. AAPS J. 7, E353-E360.
14. Svenningsson, P., Nishi, A., Fisone, G., Girault, J.-A., Nairn, A. C., and Greengard, P. (2004) DARPP-32: An Integrator of Neurotransmission. Annu. Rev. Pharmacol. Toxicol. 44, 269-296.
15. Fernandez, É, S, R., Girault, J.-A., and Novère, N. L. (2006) DARPP-32 Is a Robust Integrator of Dopamine and Glutamate Signals. PLoS Comput. Biol. 2, e176.
16. Chergui, K., Svenningsson, P., and Greengard, P. (2005) Physiological Role for Casein Kinase 1 in Glutamatergic Synaptic Transmission. J. Neurosci. 25, 6601-6609.
17. Li, D., Herrera, S., Bubula, N., Nikitina, E., Palmer, A. A., Hanck, D. A., Loweth, J. A., and Vezina, P. (2011) Casein kinase 1 enables nucleus accumbens amphetamine-induced locomotion by regulating AMPA receptor phosphorylation. J. Neurochem. 118, 237-247.
18. Nairn, A. C., Svenningsson, P., Nishi, A., Fisone, G., Girault, J.-A., and Greengard, P. (2004) The role of DARPP-32 in the actions of drugs of abuse. Neuropharmacology 47 (Supplement 1), 14-23.
19. Mahajan, S. D., Aalinkeel, R., Reynolds, J. L., Nair, B. B., Sykes, D. E., Hu, Z., Bonoiu, A., Ding, H., Prasad, P. N., and Schwartz, S. A. (2009) Therapeutic Targeting of "DARPP-32 ": A Key Signaling Molecule in the Dopiminergic Pathway for the Treatment of Opiate Addiction. International Review of Neurobiology (Hari Shanker, S., Ed.), Chapter 8, pp 199-222, Academic Press, New York.
20. Bryant, C., Graham, M., Distler, M., Munoz, M., Li, D., Vezina, P., Sokoloff, G., and Palmer, A. (2009) A role for casein kinase 1 epsilon in the locomotor stimulant response to methamphetamine. Psychopharmacology 203, 703-711.
21. Bryant, C. D., Parker, C. C., Zhou, L., Olker, C., Chandrasekaran, R. Y., Wager, T. T., Bolivar, V. J., Loudon, A. S., Vitaterna, M. H., Turek, F. W., and Palmer, A. A. (2012) Csnk1e Is a Genetic Regulator of Sensitivity to Psychostimulants and Opioids. Neuropsychopharmacology 37, 1026-1035.
22. Mente, S., Arnold, E., Butler, T., Chakrapani, S., Chandrasekaran, R., Cherry, K., DiRico, K., Doran, A., Fisher, K., Galatsis, P., Green, M., Hayward, M., Humphrey, J., Knafels, J., Li, J., Liu, S., Marconi, M., McDonald, S., Ohren, J., Paradis, V., Sneed, B., Walton, K., and Wager, T. (2013) Ligand-Protein Interactions of Selective Casein Kinase 1δ Inhibitors. J. Med. Chem. 56, 6819-6828.
23. Badura, L., Swanson, T., Adamowicz, W., Adams, J., Cianfrogna, J., and Fisher, K. (2007) An inhibitor of casein kinase I epsilon induces phase delays in circadian rhythms under free-running and entrained conditions. J. Pharmacol. Exp. Ther. 322, 730-738.
24. Wager, T. T., Chandrasekaran, R. Y., Hou, X., Troutman, M. D., Verhoest, P. R., Villalobos, A., and Will, Y. (2010) Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes. ACS Chem. Neurosci. 1, 420-434.
25. Wager, T. T., Hou, X., Verhoest, P. R., and Villalobos, A. (2010) Moving beyond rules: The development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem. Neurosci. 1, 435-449.
26. Mente, S., Doran, A., and Wager, T. T. (2012) Getting the MAX out of computational models: The prediction of unbound-brain and unbound-plasma maximum concentrations. ACS Med. Chem. Lett. 3, 515-519.
27. Wager, T. T., Kormos, B. L., Brady, J. T., Will, Y., Aleo, M. D., Stedman, D. B., Kuhn, M., and Chandrasekaran, R. Y. (2013) Improving the Odds of Success in Drug Discovery: Choosing the Best Compounds for in Vivo Toxicology Studies. J. Med. Chem. 56, 9771-9779.
28. Marchant, N. J., Li, X., and Shaham, Y. (2013) Recent developments in animal models of drug relapse. Curr. Opin. Neurobiol. 23, 675-683.
29. Morgan, P., Van Der Graaf, P. H., Arrowsmith, J., Feltner, D. E., Drummond, K. S., Wegner, C. D., and Street, S. D. A. (2012) Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discovery Today 17, 419-424.
30. Ertl, P. (2008) Polar surface area. Methods Princ. Med. Chem. 37, 111-126.
31. Feng, B., Mills, J. B., Davidson, R. E., Mireles, R. J., Janiszewski, J. S., Troutman, M. D., and de Morais, S. M. (2008) In vitro Pglycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab. Dispos. 36, 268-275.
32. Hosea, N. A., Collard, W. T., Cole, S., Maurer, T. S., Fang, R. X., Jones, H., Kakar, S. M., Nakai, Y., Smith, B. J., Webster, R., and Beaumont, K. (2009) Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J. Clin. Pharmacol. 49, 513-533.
33. Gao, H., Yao, L., Mathieu, H. W., Zhang, Y., Maurer, T. S., Troutman, M. D., Scott, D. O., Ruggeri, R. B., and Lin, J. (2008) In silico modeling of nonspecific binding to human liver microsomes. Drug Metab. Dispos. 36, 2130-2135.
34. Newman, A. H., Beuming, T., Banala, A. K., Donthamsetti, P., Pongetti, K., LaBounty, A., Levy, B., Cao, J., Michino, M., Luedtke, R. R., Javitch, J. A., and Shi, L. (2012) Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. J. Med. Chem. 55, 6689-6699.
35. Lu, Y., Kingsbury, C., Bohnstedt, A., Ohlmeyer, M., and Paradkar, V. (2008) 8-Substituted 2-(benzimidazolyl) purine derivatives as immunosuppressants and their preparation, pharmaceutical compositions and use in the treatment of immune diseases. Patent WO2008043019A1.
36. Flotow, H., Graves, P. R., Wang, A. Q., Fiol, C. J., Roeske, R. W., and Roach, P. J. (1990) Phosphate groups as substrate determinants for casein kinase I action. J. Biol. Chem. 265, 14264-14269.
37. O'Connor, E. C., Parker, D., Rollema, H., and Mead, A. N. (2010) The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats. Psychopharmacology (Berlin, Ger.) 208, 365-376.